Asthma is a chronic inflammatory disorder of the airways characterized by inflammation, variable airflow obstruction and AHR. It is estimated that asthma affects 5--10% of adults ([@b1]). Genomewide association studies have consistently implicated IL-33 as an asthma susceptibility gene ([@b2]--[@b4]). IL-33 and its receptor ST2 function as an alarmin to alert the immune system after endothelial or epithelial cell damage during trauma, physicochemical stress or infection ([@b5]). IL-33 increased AHR *in vivo* ([@b6]) and in lung slices ([@b7]) and plays a key role in rhinovirus-induced asthma exacerbations ([@b8]). Additionally, disruption of IL-33/ST2 signalling *in vivo* during the course of experimental asthma or anaphylaxis reduced the severity of disease ([@b9]--[@b16]).

In asthma, mast cell--ASM interactions are important in the development of disordered airway physiology ([@b17]). ASM cells from asthmatics express elevated levels of IL-33 compared to healthy subjects ([@b18]), and mast cells respond to IL-33 activation ([@b19],[@b20]). We hypothesize that the IL-33/ST2 axis plays a role in mast cell--ASM interactions in asthma. We show that IL-33 expression was increased in the bronchial epithelium and ASM in asthma. IL-33 promoted ASM wound repair directly and, in an autocrine manner, augmented mast cell mediator release and, indirectly, increased ASM contraction following coculture with mast cells via upregulation of mast cell-derived IL-13. Similarly, in an *in vivo* mouse model of intratracheal cytokine installation, IL-33 induced AHR which was IL-13 dependent. Therefore, IL-33 may present an important target to modulate mast cell--ASM crosstalk in asthma.

Methods
=======

A more detailed methods section is provided in the supplement.

Subjects
--------

Asthmatic subjects had a consistent history and evidence of asthma. The study was approved by Leicestershire Ethics Committee. All patients gave their written informed consent.

Cell culture
------------

Primary human ASM cells, human lung mast cells (HLMC), human epithelial cells and the human mastocytoma cell-1 (HMC-1) cell line were isolated and cultured as previously described ([@b21]--[@b23]).

Animals
-------

Lungs were taken from BALBc (8- to 12-week-old) and C57BL6 (16- to 24-week-old) mice for precision cut lung slicing (PCLS).

Immunohistochemistry
--------------------

Bronchial biopsy sections were stained for IL-33 and assessed using a semi-quantitative intensity score (SQS) and quantitative thresholding.

Flow cytometry and immunofluorescence
-------------------------------------

IL-33 and ST2 expression was assessed by flow cytometry and immunofluorescence. Cells were counterstained with 4′,6′-diamidino-2-phenylindole (DAPI).

qPCR
----

Quantitative RT-PCR of ST2L, ST2 and IL-13 was performed and compared against the internal reference gene 18S.

ELISA
-----

IL-33 and IL-13 concentrations were quantified by ELISA.

Calcium flux
------------

The ratio of fluo-3/fura red within cells *vs* time was measured by flow cytometry. Following baseline measurements (1 min), cell flow was halted, IL-33 or calcium ionophore added, and data acquired for a further 3 min.

Cell metabolic activity assay and apoptosis measurement
-------------------------------------------------------

ASM cells were treated as indicated in [Fig. S1](#SD1){ref-type="supplementary-material"}. The CellTiter 96 Aqueous One Solution was added as per the manufacturer\'s instructions. Apoptosis was assessed by DAPI staining of nuclear morphology and annexin-V ± propidium iodide staining according to manufacturer\'s protocol.

Cell contraction
----------------

ASM cells ± HLMC (4:1 ratio) were impregnated into collagen gels. Gel surface area was measured using ImageJ (<http://rsb.info.nih.gov/ij>).

Mesoscale analysis
------------------

Cytokines and chemokines were measured in cells ± IL-33 by electrochemiluminescence detection (Mesoscale Discovery, Gaithersburg, Maryland).

Wound repair
------------

ASM cells ± IL-33, isotype control or anti-IL-33-neutralizing antibody were wounded as described previously ([@b21]). Wounds were photographed at baseline and after 18 h. Wound repair was analysed using cell^F^ software.

Histamine assay
---------------

Histamine was measured in supernatants from activated HLMC (anti-FcεR1 antibody or IL-33 for 24 h) or HLMC incubated with ASM (1:4 ratio) for 5--11 days ± IL-33, isotype control or anti-IL-33-neutralizing antibody, as previously described ([@b24]).

PCLS
----

PCLS were prepared as described previously ([@b25]). Images were captured at baseline, then every 5 min for cumulative carbachol dose responses and 2--10 min post mouse IL-33. Airway lumen size was measured using ImageJ software.

AHR and inflammation by IL-33
-----------------------------

BALBc mice were dosed intranasally with three repeated doses of murine IL-33 (5 μg). Post 3 days, cell number in the lung tissue was assessed by lung digest. AHR was measured using a flexiVent system ± neutralization of IL-13 activity using fusion protein (IL-13Rα2) administered 2 h prior to each IL-33 administration. IL-13, Gob-5 and Muc5AC mRNA expression was determined by RT-PCR, and mouse serum mMCP-1 in serum by ELISA.

Statistical analysis
--------------------

Statistical analysis was performed using GraphPad PRISM using parametric and nonparametric tests as appropriate. A *P* \< 0.05 was considered significant.

Results
=======

IL-33 expression in the ASM-bundle in asthma
--------------------------------------------

IL-33 expression was identified within the ASM-bundles in most subjects with variable intensity of expression, and within the epithelium (Fig.[1](#fig01){ref-type="fig"}A). Mast cells within the ASM-bundle infrequently coexpressed IL-33 (data not shown). The semi-quantitative intensity score (SQS) for IL-33 expression was significantly increased in mild--moderate asthma compared to healthy controls (Kruskal--Wallis *P* = 0.033; post hoc Dunn\'s pairwise comparison *P* = 0.046, Fig.[1](#fig01){ref-type="fig"}B). The correlation between SQS IL-33 ASM expression and AHR was good (*r* = −0.63, *P* \< 0.001, Fig.[1](#fig01){ref-type="fig"}C). There was no significant correlation between IL-33 expression and FEV~1~% predicted, bronchodilator reversibility, atopic status or sputum cell counts (data not shown). Epithelial IL-33 expression was also significantly increased in mild-to-moderate asthma compared to healthy controls (Kruskal--Wallis *P* = 0.047; post hoc Dunn\'s pairwise comparison *P* = 0.041, Fig.[1](#fig01){ref-type="fig"}D). The SQS and quantitative expression using thresholding were correlated for both ASM (*r* = 0.63, *P* = 0.004) and epithelium (*r* = 0.43, *P* = 0.013). Quantitative IL-33 expression was increased in the ASM and epithelium in asthmatics compared to healthy subjects, but did not reach statistical significance. Quantitative IL-33 expression in ASM correlated with AHR in those with asthma (*r* = −0.52, *P* = 0.007). The clinical characteristics of the subjects are shown in Table [1](#tbl1){ref-type="table"}.

![ASM and bronchial epithelial IL-33 expression (A) Representative photomicrographs of bronchial biopsies from an asthmatic subject illustrating isotype control, IL-33+ cell staining in ASM, submucosa (original magnification ×100), and within the ASM-bundle and epithelium (original magnification ×400). (B) Semi-quantitative scoring (SQS) of ASM IL-33. (C) Correlation between SQS ASM IL-33 and AHR in subjects with asthma. (D) Semi-quantitative scoring (SQS) of bronchial epithelium IL-33. • = healthy control, ▵ = mild--moderate asthma, ▪ = severe asthma. Horizontal bars represent the median, *P* \< 0.05, Kruskal--Wallis test, for all across-group comparisons.](all0070-0556-f1){#fig01}

###### 

Clinical characteristics of asthmatic subjects and healthy controls

                                                                        Normal           Mild--moderate asthma GINA 1--3                   Severe asthma GINA 4--5
  --------------------------------------------------------------------- ---------------- ------------------------------------------------- -------------------------------------------------
  Number                                                                9                18                                                12
  Age[†](#tf1-2){ref-type="table-fn"}                                   45 (30--55)      56 (28--63)                                       51 (45--62)
  Male/Female                                                           6/3              5/13                                              6/6
  Atopy *n* (%)                                                         4 (44)           11 (61)                                           10 (83)
  Inhaled corticosteroids BDP μg/day[†](#tf1-2){ref-type="table-fn"}    0                0 (0--500)                                        1800 (1600--2000)
  Oral corticosteroid mg/day[†](#tf1-2){ref-type="table-fn"}            0                0                                                 0 (0--7.5)
  Methacholine PC~20~FEV~1~ (mg/ml)[‡](#tf1-3){ref-type="table-fn"}     \>16             0.5 (0.3--1.0)[\*](#tf1-1){ref-type="table-fn"}   2.4 (1.2--5.0)[\*](#tf1-1){ref-type="table-fn"}
  FEV1% predicted[§](#tf1-4){ref-type="table-fn"}                       95 (3)           86 (5)                                            77 (7)[\*](#tf1-1){ref-type="table-fn"}
  Pre-BD FEV1/FVC %[§](#tf1-4){ref-type="table-fn"}                     82 (2)           72 (2)[\*](#tf1-1){ref-type="table-fn"}           67 (4)[\*](#tf1-1){ref-type="table-fn"}
  BD response (%)[§](#tf1-4){ref-type="table-fn"}                       1 (1)            11 (4)[\*](#tf1-1){ref-type="table-fn"}           9 (2)[\*](#tf1-1){ref-type="table-fn"}
  Sputum cell counts                                                                                                                       
   Total cell count (×10^6^/g sputum)[†](#tf1-2){ref-type="table-fn"}   1.0 (0.8--3.7)   2.5 (0.7--3.2)                                    3.7 (2.3--7.9)[\*](#tf1-1){ref-type="table-fn"}
   Eosinophil %[†](#tf1-2){ref-type="table-fn"}                         0.6 (0.1--0.9)   0.4 (0.1--4.2)                                    4.0 (2.3--7.9)[\*](#tf1-1){ref-type="table-fn"}
   Neutrophil %[†](#tf1-2){ref-type="table-fn"}                         60 (47--71)      51 (25--74)                                       71 (57--89)
  Bronchial biopsy IL-33 expression                                                                                                        
   Airway smooth muscle (SQS)[†](#tf1-2){ref-type="table-fn"}           1 (0.5)          1.75 (0.75)[\*](#tf1-1){ref-type="table-fn"}      1.13 (1.4)
   Bronchial epithelium (SQS)[†](#tf1-2){ref-type="table-fn"}           2 (1)            4 (1.5)[\*](#tf1-1){ref-type="table-fn"}          4 (1.75)

SQS, semi-quantitative score, BDP, beclomethasone dipropionate equivalent.

*P* \< 0.05 compared to control.

Median (IQR), BD-bronchodilator.

Geometric mean (95% CI).

Mean (SEM).

IL-33 expression by ASM, mast cells and bronchial epithelium
------------------------------------------------------------

IL-33 expression was identified in human ASM, HLMC, HMC-1 and epithelial cells by immunofluorescence (Fig.[2](#fig02){ref-type="fig"}A) and flow cytometry (Fig.[2](#fig02){ref-type="fig"}B,C). IL-33 expression was not different between ASM cells derived from asthmatic subjects compared to healthy controls (data not shown). IL-33 was spontaneously released from ASM, HLMC, HMC-1 and epithelial cells as measured by ELISA after 24 h (Fig.[2](#fig02){ref-type="fig"}D).

![IL-33 and ST2 expressed by *ex vivo* human cells. (A) IL-33 expression was confirmed in ASM, HLMC, HMC-1 and epithelial cells by immunofluorescence (nuclei stained blue, IL-33 stained green, isotype control shown as inset, magnification ×400, *n* = 3). (B) Example flow cytometry histograms in ASM cells, HLMC and epithelial cells represent populations of IL-33 (black line) plotted with the corresponding isotype control (grey line). (C) Quantification of total cell IL-33 in ASM (*n* = 6), HLMC (*n* = 7), HMC-1 (*n* = 5) and epithelial cells (*n* = 11, \*\<0.05 *vs* isotype control). (D) IL-33 was measured in ASM (*n* = 10), HLMC (*n* = 7), HMC-1 (*n* = 4) and epithelial cell (*n* = 7) supernatants by ELISA. (E) IL-33 receptor (ST2L and ST2) mRNA expression analysed by qPCR in ASM, HLMC and HMC-1 cells. Data were normalized to 18sRNA and expressed following the equation ()x10^6^). (F) IL-33 receptor mRNA expression in unstimulated and stimulated (IL-33, 50 ng/ml, 24 h) HLMC analysed by qPCR. Data are presented as fold difference on a log~2~ scale (−ΔΔ*C*~t~, *n* = 3,\*\<0.05, \*\*\<0.01 *vs* unstimulated cells). (G) Cell surface and total cell ST2 receptor expression was measured by flow cytometry in unstimulated and stimulated (50 ng/ml, IL-33 for 48 h) ASM, HLMC and HMC-1 cells (*n* = 3). All data presented as mean ± SEM. Statistical differences were assessed using *t*-tests.](all0070-0556-f2){#fig02}

mRNA expression of IL-33 receptors ST2L (long transducing isoform) and ST2 (short decoy soluble form) was evident in mast cells, but not in ASM cells (Fig.[2](#fig02){ref-type="fig"}E). A two- and threefold increase in ST2L and ST2 mRNA expression were observed respectively in HLMC following IL-33 stimulation (50 ng/ml, 24 h, Fig.[2](#fig02){ref-type="fig"}F), but not in ASM cells (*n* = 3, data not shown). Although ST2 cell surface expression was not identified in unstimulated ASM, HLMC and HMC-1 cells by flow cytometry, IL-33 stimulation (50 ng/ml, 48 h) significantly upregulated ST2 surface expression (Fig.[2](#fig02){ref-type="fig"}G). Total cell ST2 expression was apparent in all unstimulated cell types and increased poststimulation with IL-33 (Fig.[2](#fig02){ref-type="fig"}G).

Functional responses of ASM and mast cells to IL-33
---------------------------------------------------

IL-33 (50--200 ng/ml) triggered Ca^2+^ flux with increased intracellular calcium in ASM and HMC-1 cells as indicated by an increase in the fluo 3/fura red ratio, with a maximum response at 100 ng/ml (Fig.[3](#fig03){ref-type="fig"}A). IL-13 mRNA expression (Fig.[3](#fig03){ref-type="fig"}B) and protein release (Fig.[3](#fig03){ref-type="fig"}C) were significantly upregulated in HLMC stimulated with IL-33 (50 ng/ml, 24 h) with increased histamine release independent of FcεR1 cross-linking also observed (Fig.[3](#fig03){ref-type="fig"}D); HMC-1 (*n* = 4), but not ASM (*n* = 6), cells released CCL2, 4, 5, CXCL8 and 10 significantly following IL-33 incubation (10 ng/ml, 24 h) compared to control (data not shown).

![Functional responses to IL-33. (A) Calcium flux in ASM (*n* = 4) and HMC-1 cells (*n* = 4--9) in the presence of IL-33 or calcium ionophore. ΔGMFI equates to total stimulated GMFI minus matched baseline GMFI (\*\<0.05, \*\*\<0.01 compared to baseline GMFI). (B) IL-13 mRNA expression in HLMC ± IL-33 (50 ng/ml, 24 h) analysed by qPCR using the ΔΔ*C*~t~ method. Data are presented as fold difference on a log~2~ scale (−ΔΔ*C*~t~, *n* = 3, \*\*\<0.01 *vs* unstimulated cells). (C) IL-13 protein release in HLMC stimulated with anti-FcεR1 (1:1000) and IL-33 (50 ng/ml) for 24 h (*n* = 10--15). (D) Histamine release in HLMC stimulated with anti-FcεR1 (1:1000) and IL-33 (50 ng/ml) for 24 h (*n* = 12--18) (\*\*\<0.01, \*\*\*\<0.001 *vs* unstimulated HLMC). (E) Percentage wound repair by ASM ± IL-33 (50 ng/ml), isotype control or IL-33-neutralizing antibody for 18 h with representative ASM wound repair pictures at 18 h. (F) Percentage contraction in PCLS to cumulative concentrations of carbachol (Cch) pretreated without (unprimed), or with IL-33 (100 ng/ml) for 20 h. Area under the curve gel contraction between group comparisons was made by paired *t*-test. Each point represents mean ± SEM using 1--3 lung slices, 4--8 mice. (G) Collagen gel contraction in ASM cells primed with IL-33 (50 ng/ml over 48 h) impregnated in collagen gels for 3 days (*n* = 4). All data presented as mean ± SEM. Statistical differences were assessed using the t-tests.](all0070-0556-f3){#fig03}

ASM wound repair was promoted by both exogenous and ASM-derived IL-33 (Fig.[3](#fig03){ref-type="fig"}E) as demonstrated by an IL-33-neutralizing antibody reducing wound repair in both control and IL-33-treated cells (Fig.[3](#fig03){ref-type="fig"}E). Neither ASM proliferation nor survival was modulated by exogenous IL-33 or neutralization of ASM-derived IL-33 (see [Fig. S1](#SD1){ref-type="supplementary-material"}).

Direct addition of IL-33 (100 ng/ml) to PCLS from BALBc and C57BL6 mice (*n* = 5) did not affect bronchoconstriction over 2--10 min (data not shown). Pretreatment of PCLS from BALBc (Fig.[3](#fig03){ref-type="fig"}F) and C57BL6 (*n* = 4, data not shown) mice with IL-33 (100 ng/ml, 20 h) had no effect on Cch-induced luminal diameter. Contraction of human ASM cells primed with IL-33 (50 ng/ml, 48 h) and embedded within collagen gels was not different to unprimed ASM cells over 3 days (Fig.[3](#fig03){ref-type="fig"}G).

Previously, we have shown that HLMC/ASM cell coculture promotes HLMC survival/proliferation and results in increased α-SMA expression ([@b23]) and histamine release ([@b24]). The contribution of endogenous IL-33 to these changes was assessed.

HLMC cocultured with ASM for 7 days demonstrated increased proliferation compared to HLMC monocultures as determined by CFSE fluorescence (Fig.[4](#fig04){ref-type="fig"}B) and cell counts (Fig.[4](#fig04){ref-type="fig"}C and D). This was unaffected by IL-33-neutralizing antibody. ASM cells counts were significantly increased following coculture with HLMC lysate for 7 days compared to monoculture; however, this was unaffected by IL-33-neutralizing antibody (Fig.[4](#fig04){ref-type="fig"}E).

![Mast cell and lysate coculture with ASM cells. (A--G) ASM cells were cultured alone or in coculture with HLMC or HLMC lysates and incubated with IL-33 and/or IL-33-neutralizing or isotype control antibodies for 7 days. (A) Representative flow cytometric dot plot showing ASM and HLMC (prelabelled with CFSE) cocultured for 7 days. CFSE-positive cells were gated; histogram shows CFSE GMFI in cocultured HLMC *vs* HLMC alone at baseline. Quantification of HLMC proliferation in (B) indicated by a reduction in CFSE gMFI in ASM/HLMC cocultures (*n* = 4) and (C) by cell counts in ASM/HLMC cocultures. ASM cell counts in (D) following ASM/HLMC coculture (*n* = 4) and (E) with HLMC lysate (*n* = 4). (F) Example histogram of α-SMA expression in ASM cells alone and in coculture with HLMC lysate. (G) ΔGMFI of α-SMA expression in ASM ± HLMC lysate (*n* = 4). (H) Histamine release by HLMC in coculture with ASM (*n* = 4). (I) Collagen gel contraction in cocultured cells ± IL-33 (50 ng/ml), isotype control or IL-13-neutralizing antibody over 1--3 days (\**P* \< 0.05, coculture+IL-33+isotype control *vs* coculture+IL-33+anti-IL-13-neutralizing antibody). Representative gel photographs at day 3. All data presented as mean ± SEM. Statistical differences were assessed using paired *t*-tests (\*\<0.05).](all0070-0556-f4){#fig04}

ASM cells cocultured with HLMC lysate showed increased α-SMA GMFI compared to ASM monocultures, but this was unaffected by IL-33-neutralizing antibody (Fig.[4](#fig04){ref-type="fig"}F,G). Histamine release was increased from HLMC following coculture with ASM compared to HLMC monocultures reaching significance after 11 days; however, this was unaffected by IL-33 or IL-33-neutralizing antibody (Fig.[4](#fig04){ref-type="fig"}H).

Critically, when both ASM and HLMCs are impregnated into collagen gels following coculture and then stimulated directly with exogenous IL-33, increased gel contraction is seen compared to untreated cells. This can be inhibited by an IL-13-neutralizing antibody but is unaffected by the corresponding isotype control antibody (Fig.[4](#fig04){ref-type="fig"}I). HLMCs alone did not elicit gel contraction, ASM/HLMC cocultures did not increase gel contraction compared to ASM alone in the absence of exogenous IL-33, with no effect of IL-13 neutralization over 3 days on this contraction (data not shown, *P* = 0.38, *n* = 3). HLMC IL-13 release was unaffected by coculture with ASM or incubation with ASM-conditioned media (data not shown). These data suggest IL-33 can augment ASM contractility indirectly via upregulation of HLMC IL-13 release. However, endogenous release of IL-33 by ASM is insufficient to activate HLMC IL-13 release in this system.

IL-33 induces AHR *in vivo* and is IL-13 dependent
--------------------------------------------------

IL-33 induced a profound AHR in naïve BALBc mice after intranasal challenge with increase in total lung cells (Fig.[5](#fig05){ref-type="fig"}B), mast cell activation with increased serum concentrations of mouse mast cell protease-1 (mMCP-1, Fig.[5](#fig05){ref-type="fig"}C) and increased expression in the airway of MUC5ac, Gob-5 (Fig.[5](#fig05){ref-type="fig"}D) and IL-13 (Fig.[5](#fig05){ref-type="fig"}E). Interestingly, similar to results in the human coculture system, neutralization of IL-13 activity (using IL-13Rα2 fusion protein administered 2 h prior to each IL-33 administration) abrogated AHR significantly (Fig.[5](#fig05){ref-type="fig"}F).

![Role of IL-33 in an *in vivo* mouse model. (A) BALBc mice were dosed intranasally with 3 repeated doses of 5 μg (one per day) of murine IL-33. (B) Total cell numbers in lung tissue were assessed after IL-33 administration by lung digest. (C) Mast cell activation was determined by measurement of mMCP-1 release in serum by ELISA. (D) MUC5ac, Gob5 and (E) IL-13 expression assessed in the lung by TaqMan qPCR. All data presented as mean ± SEM, \**P* \< 0.05, \*\*\**P* \< 0.001 compared with PBS control, *n* = 5--18 mice/group from 1-3 separate experiments. (F) IL-13 signalling was blocked using an IL-13Rα2 fusion protein administered 2 h prior to each IL-33 administration. Data are expressed as mean ± SEM, *n* = 5--18 mice/group from 1 to 3 separate experiments, \**P* \< 0.05 by two-way [anova]{.smallcaps} compared with PBS control-treated mice.](all0070-0556-f5){#fig05}

Discussion
==========

We demonstrated IL-33 expression *in vivo* and *in vitro* in the bronchial epithelium and ASM and in primary mast cells. The ST2 receptor was expressed by mast cells and ASM by total cell staining and at the surface following IL-33 treatment. IL-33 promoted mast cell activation and ASM wound repair and indirectly promoted contraction via upregulation of mast cell-derived IL-13. This suggests that IL-33 may present an important target to modulate mast cell--ASM crosstalk in asthma.

We report here that IL-33 expression was evident in the bronchial epithelium and ASM-bundle, with expression increased in mild--moderate asthmatics compared to healthy controls. This is consistent with earlier reports in adult asthma ([@b18],[@b26]), but contrasts with paediatric severe asthma in which neither epithelial nor ASM IL-33 expression was increased compared to controls ([@b6]). We found expression in the ASM, but not epithelium was correlated to the degree of AHR. Primary mast cells and ASM expressed IL-33 and ST2 constitutively as assessed by total cell staining and at the surface following IL-33 treatment. Localization of IL-33 was detected primarily within the nuclei as seen in human nasal fibroblasts ([@b27]).

We demonstrated for the first time that IL-33 had no effect on ASM proliferation, apoptosis and synthetic capacity, but both exogenous and ASM-derived IL-33 played an important role in ASM wound repair. Thus, endogenously expressed IL-33 in ASM observed *in vivo* in humans may contribute to ASM repair via migration following damage secondary to physical, mechanical or inflammatory insults. Further work is required to determine the mechanism via which IL-33 stimulates ASM migration; however, in support of our observations, recombinant IL-33 has been shown to have direct effects on chemotaxis of myofibroblasts, fibrocytes, neutrophils, nuocytes and microglia cells ([@b28]--[@b31]).

IL-33 triggered calcium flux in both ASM and HMC-1 cells, in keeping with other studies showing that IL-33 can enhance calcium elevation autonomously or in synergy with other mediators ([@b32]) and that IL-33 can activate calcium-dependent downstream signalling ([@b33]--[@b35]). Although the mechanism by which IL-33 causes calcium elevation has not been studied, other members of the IL-1 family have been shown to induce calcium signalling in a manner which is GPCR dependent involving both extracellular calcium and intracellular calcium stores ([@b36]). Due to the rapid response, the effect of IL-33 on \[Ca^2+^\]~i~ elevation is likely to be a direct effect on ASM, but in the mast cells it could be a synergistic response in conjunction with preformed mediators released by mast cells.

Importantly, IL-33 is a critical cytokine in the initiation and exacerbation of inflammatory responses and enhanced IgE production in naïve wild-type mice, histamine release ([@b37]) and tryptase expression ([@b38]) in mouse mast cells. Similarly, human mast cells respond to IL-33 activation ([@b19],[@b20]). Here, we found that IL-33 upregulated ST2, IL-13 and histamine release acutely by mast cells independent of FcεR1 cross-linking. Mast cell localization to the ASM-bundle is a notable feature of asthma, and therefore, ASM-derived IL-33 might play an important role in IgE-independent mast cell activation in the asthmatic airway. In addition, mast cell proteases have recently been shown to increase the activity of IL-33 ([@b39]).

Indeed, mast cell number within the ASM-bundle is related to the degree of AHR ([@b17]). Coculture of primary ASM and mast cells promotes mast cell activation ([@b24]), differentiation ([@b40]), survival, proliferation and phenotypic changes in ASM ([@b23],[@b24],[@b40]). Neutralization of IL-33 in ASM/mast cell cocultures had no effect on mast cell proliferation or histamine release, or α-SMA expression by ASM cells. Interestingly, coculture of ASM and mast cells together with the addition of IL-33 increased collagen gel contraction. This was IL-13 dependent, and the enhanced contraction in response to IL-33 was normalized following IL-13 neutralization. IL-33 had no direct effect on human ASM contraction or *ex vivo* PCLS from BALBc or C57BL6 mice. We found that in a mouse model system, IL-33 induced AHR, mMCP-1, MUC5ac, Gob-5 and IL-13 expression that was abrogated with IL-13Rα2 fusion protein supporting the human findings of IL-13-dependent IL-33 induction of ASM contraction possibly via mast cell activation. These findings are supported by two independent recent studies. Barlow and colleagues ([@b7]) examined the response to methacholine in the PCLS *ex vivo* model and demonstrated that IL-33 mediated increased AHR that was IL-13 dependent. Saglani and colleagues ([@b6]) found that IL-33 induction of AHR was IL-13 dependent prior to prolonged exposure to house dust mite, but following this exposure was partly IL-13 independent. However, the exact mechanism via which IL-33 mediates IL-13-dependent ASM contraction remains to be elucidated.

Critically, in contrast to human asthma, mast cell localization to the ASM is not a feature of murine models of asthma. Therefore, although the animal models support the concept that IL-33-induced AHR is IL-13 dependent, whether mast cells are critical in these models is uncertain. Indeed, IL-13 has been shown to be produced by Th2 cells ([@b41]), NKT cells ([@b42]), basophils ([@b43]) and ILC2s ([@b44],[@b45]), the latter two of which can be dependent on IL-33. Nevertheless, IL-13 release by mast cells in human disease secondary to IL-33 activation remains likely to be important in human disease as these mast cells express IL-13 *in vivo* ([@b46],[@b47]) and are the most abundant inflammatory cell in the ASM-bundle ([@b17]). Interestingly, we were unable to demonstrate that constitutive ASM-derived IL-33 was sufficient to induce IL-13 release from mast cells in coculture, and therefore, it is likely that either upregulation of IL-33 release by ASM *in vivo* or contributions from other cellular sources such as the epithelium might be important in activating IL-13 release from mast cells in asthma. The exact role of IL-33 in human disease will require future clinical studies targeting the IL-33 axis.

In conclusion, our findings showed that IL-33 promoted mast cell activation and ASM wound repair and indirectly promoted both ASM contraction *in vitro* via upregulation of mast cell-derived IL-13 and also IL-13-dependent AHR *in vivo*. Therefore, IL-33 might be an important novel therapeutic target to modulate mast cell--ASM crosstalk in asthma.
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